{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=45&sponsor=Genentech%2C+Inc.", "query": { "sponsor": "Genentech, Inc.", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 1397, "total_pages": 140, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=46&sponsor=Genentech%2C+Inc.&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=44&sponsor=Genentech%2C+Inc.&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T18:09:17.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00090051", "title": "FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 552, "start_date": "2003-07-31", "completion_date": "2012-05-31", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Fresno, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090051" }, { "nct_id": "NCT05650723", "title": "Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "Zanubrutinib Pill", "type": "DRUG" }, { "name": "Venetoclax Pill", "type": "DRUG" }, { "name": "Obinutuzumab Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-05-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650723" }, { "nct_id": "NCT00651482", "title": "Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Neoplasms", "Kidney (Renal Cell) Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandy Srinivas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2008-08", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00651482" }, { "nct_id": "NCT00001020", "title": "A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1IIIB", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 28, "start_date": null, "completion_date": "1995-02", "has_results": false, "last_update_posted_date": "2012-05-18", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 3, "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001020" }, { "nct_id": "NCT04477759", "title": "Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Neoplasm" ], "interventions": [ { "name": "50 Gy Radiation Therapy", "type": "RADIATION" }, { "name": "55 Gy Radiation Therapy", "type": "RADIATION" }, { "name": "60 Gy Radiation Therapy", "type": "RADIATION" }, { "name": "Concurrent Atezolizumab", "type": "DRUG" }, { "name": "Adjuvant Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-01-26", "completion_date": "2025-04-14", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477759" }, { "nct_id": "NCT01794520", "title": "Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2012-10-10", "completion_date": "2021-11-29", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01794520" }, { "nct_id": "NCT00911820", "title": "Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Docetaxel", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2009-07", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911820" }, { "nct_id": "NCT00654836", "title": "Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "ABI-007", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-10", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-09-14", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 6, "location_summary": "Downers Grove, Illinois • Geneva, Illinois • Maywood, Illinois + 3 more", "locations": [ { "city": "Downers Grove", "state": "Illinois" }, { "city": "Geneva", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Naperville", "state": "Illinois" }, { "city": "Rockford", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654836" }, { "nct_id": "NCT00392665", "title": "Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" }, { "name": "Sulindac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2006-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-04-13", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392665" }, { "nct_id": "NCT03713944", "title": "Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC Stage IV", "NSCLC, Recurrent" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nasser Hanna", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-11-15", "completion_date": "2021-12-16", "has_results": true, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-10-30T18:09:17.521Z", "location_count": 7, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03713944" } ] }